Yuan Liu - LakeShore Biopharma Head Research
| LSB Stock | 2.75 0.23 7.72% |
Executive
Yuan Liu is Head Research of LakeShore Biopharma Co,
| Age | 37 |
| Address | Building No. 2, Beijing, China, 102629 |
| Phone | 86 10 8920 2086 |
| Web | https://www.ysbiopharm.com |
LakeShore Biopharma Management Efficiency
The company has Return on Asset of (0.1385) % which means that on every $100 spent on assets, it lost $0.1385. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.6599) %, meaning that it generated no profit with money invested by stockholders. LakeShore Biopharma's management efficiency ratios could be used to measure how well LakeShore Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.29. In addition to that, Return On Capital Employed is expected to decline to -0.66. At present, LakeShore Biopharma's Non Currrent Assets Other are projected to decrease significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 10.1 M, whereas Total Assets are forecasted to decline to about 944.3 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Kristine Campbell | U Haul Holding | 48 | |
| Jennifer Settles | U Haul Holding | N/A | |
| Stephen Wright | Avis Budget Group | N/A | |
| Sally Shanks | Willscot Mobile Mini | 47 | |
| Jason Berg | U Haul Holding | 51 | |
| Grant JD | Air Lease | 61 | |
| Thomas JD | Park Hotels Resorts | 52 | |
| Daniel Verwholt | Air Lease | N/A | |
| R Singh | Life Time Group | 51 | |
| Joseph Donegan | Willscot Mobile Mini | 73 | |
| David Beker | Air Lease | N/A | |
| CCN ND | Life Time Group | N/A | |
| Shirley Lu | Air Lease | N/A | |
| Keith Dieruf | Life Time Group | N/A | |
| Jason Thunstrom | Life Time Group | N/A | |
| Graeme Parkes | Willscot Mobile Mini | 51 | |
| Eric Hoogenkamp | Air Lease | N/A | |
| Diem Larsen | Park Hotels Resorts | N/A | |
| MD MBA | U Haul Holding | 46 | |
| Peter Rego | Vestis | N/A | |
| Jason Arnold | Air Lease | N/A | |
Management Performance
| Return On Equity | -0.66 | ||||
| Return On Asset | -0.14 |
LakeShore Biopharma Co, Leadership Team
Elected by the shareholders, the LakeShore Biopharma's board of directors comprises two types of representatives: LakeShore Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of LakeShore. The board's role is to monitor LakeShore Biopharma's management team and ensure that shareholders' interests are well served. LakeShore Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, LakeShore Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Dave Chenn, CoCEO Board | ||
| CFA MBA, President Officer | ||
| Yuan Liu, Head Research | ||
| MS MBA, Interim Director | ||
| Zenaida MD, Chief Officer | ||
| Gang Li, Head Sales | ||
| Zhiyuan Ran, Head Department | ||
| Wang Xu, Chief Officer |
LakeShore Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is LakeShore Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.66 | ||||
| Return On Asset | -0.14 | ||||
| Profit Margin | (0.76) % | ||||
| Operating Margin | (0.69) % | ||||
| Current Valuation | 139.31 M | ||||
| Shares Outstanding | 190.81 M | ||||
| Shares Owned By Insiders | 81.34 % | ||||
| Shares Owned By Institutions | 2.68 % | ||||
| Number Of Shares Shorted | 47.52 K | ||||
| Price To Book | 1.39 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether LakeShore Biopharma Co, is a strong investment it is important to analyze LakeShore Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact LakeShore Biopharma's future performance. For an informed investment choice regarding LakeShore Stock, refer to the following important reports:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in LakeShore Biopharma Co,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of LakeShore Biopharma. If investors know LakeShore will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about LakeShore Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.57) | Revenue Per Share 5.363 | Quarterly Revenue Growth 0.277 | Return On Assets (0.14) | Return On Equity (0.66) |
The market value of LakeShore Biopharma Co, is measured differently than its book value, which is the value of LakeShore that is recorded on the company's balance sheet. Investors also form their own opinion of LakeShore Biopharma's value that differs from its market value or its book value, called intrinsic value, which is LakeShore Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because LakeShore Biopharma's market value can be influenced by many factors that don't directly affect LakeShore Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between LakeShore Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if LakeShore Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, LakeShore Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.